文献速递复苏、休克与脓毒症心脑血管急症

院外心脏骤停患者的合并症与生存结局

Comorbidity and survival in out-of-hospital cardiac arrest.
PubMed 文献 · Resuscitation · 2018-10-10
一句话结论瑞典全国注册研究显示,院外心脏骤停患者合并症越多,30天生存率越低,且在校正复苏相关因素后关联仍存在。

该研究纳入2011至2015年瑞典全国心肺复苏注册中所有目击者目击的院外心脏骤停患者,并与国家患者注册数据库合并以评估合并症。共纳入12012例患者,1598例(13%)存活至30天。最常见合并症为充血性心力衰竭(29%)、心肌梗死(24%)和无并发症糖尿病(23%)。肾脏疾病、伴并发症糖尿病、无并发症糖尿病、充血性心力衰竭和转移性癌与30天生存率降低显著相关;Charlson合并症指数(CCI)越高,30天生存机会越低(CCI 3-4:校正OR 0.82;CCI 5-6:校正OR 0.62;CCI >6:校正OR 0.51,均以CCI 0-2为参照)。合并症增加还与自主循环恢复(ROSC)及入院时ROSC的 odds 降低相关。

要点

  • 在12012例目击者目击的院外心脏骤停患者中,合并症负担越重,30天生存率越低:CCI 3-4校正OR 0.82(95%CI 0.68-0.99),CCI 5-6为0.62(95%CI 0.47-0.83),CCI >6为0.51(95%CI 0.36-0.72),均以CCI 0-2为参照。
  • 特定合并症与30天生存率降低独立相关:肾脏疾病OR 0.53(95%CI 0.53-0.72)、伴并发症糖尿病OR 0.65(95%CI 0.49-0.84)、无并发症糖尿病OR 0.63(95%CI 0.52-0.75)、充血性心力衰竭OR 0.84(95%CI 0.71-0.99)、转移性癌OR 0.61(95%CI 0.40-0.93)。
  • 合并症增加还与自主循环恢复(ROSC)及入院时ROSC的 odds 降低相关。
  • 该研究为全国性注册研究,共纳入12012例患者,其中1598例(13%)存活至30天。

适用人群与场景

  • 2011至2015年瑞典全国心肺复苏注册中所有目击者目击的院外心脏骤停患者。

研究设计与关键结果

  • 研究类型:全国性注册研究;样本量:12012例;人群:目击者目击的院外心脏骤停患者;暴露:合并症(Charlson合并症指数及具体合并症);主要终点:30天生存。
  • 30天生存率:1598/12012例(13%)。
  • 最常见合并症:充血性心力衰竭29%、心肌梗死24%、无并发症糖尿病23%。
  • 校正人口学特征及复苏相关因素(可电击初始心律、旁观者心肺复苏、骤停地点)后,与30天生存率降低显著相关的合并症:肾脏疾病OR 0.53(95%CI 0.53-0.72)、伴并发症糖尿病OR 0.65(95%CI 0.49-0.84)、无并发症糖尿病OR 0.63(95%CI 0.52-0.75)、充血性心力衰竭OR 0.84(95%CI 0.71-0.99)、转移性癌OR 0.61(95%CI 0.40-0.93)。
  • 以CCI 0-2为参照,CCI 3-4的校正OR为0.82(95%CI 0.68-0.99),CCI 5-6为0.62(95%CI 0.47-0.83),CCI >6为0.51(95%CI 0.36-0.72)。
  • 合并症增加还与ROSC及入院时ROSC的 odds 降低相关。

证据类型、等级与局限

  • 证据类型:全国性注册研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,合并症负担增加与院外心脏骤停后30天生存率降低相关,该关联在校正协变量后仍存在。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients suffering out-of-hospital cardiac arrest (OHCA) have a poor prognosis but survival among subgroups differs greatly. Previous studies have shown conflicting results on whether patient comorbidity affects outcome. The aim of this national study was to investigate the effect of comorbidity on outcome after OHCA in Sweden.

METHODS: We included all patients with bystander-witnessed OHCA from 2011 to 2015 in the national Swedish Registry of Cardiopulmonary Resuscitation. In order to assess comorbidity, the database was merged with the comprehensive National Patient Registry, which includes all out-patient and in-patient care in Sweden. The Charlson comorbidity index (CCI) and the specific comorbidity conditions constituting the CCI was used to identify whether comorbidity was associated with outcome.

RESULTS: A total of 12,012 patients were included in the study. Of these, 1598 patients survived to 30 days (13%). The most common comorbidities were a history of congestive heart failure (29%), myocardial infarction (24%), and diabetes without complications (23%). Renal disease (odds ratio [OR] 0.53; 95% CI 0.53‒0.72), diabetes with complications (OR 0.65; 95% CI 0.49‒0.84), diabetes without complications (OR 0.63; 95% CI 0.52‒0.75), congestive heart failure (OR 0.84; 95% CI 0.71‒0.99), and metastatic carcinoma (OR 0.61; 95% CI 0.40‒0.93) were significantly associated with a reduced chance of 30-day survival when adjusted for demographic characteristics and also resuscitation-associated factors such as shockable initial rhythm, bystander cardiopulmonary resuscitation (CPR), and place of arrest. With increasing comorbidity, the chance of 30-day survival decreased: adjusted OR was 0.82 (59% CI 0.68-0.99) for CCI 3-4, 0.62 (95% CI 0.47-0.83) for CCI 5-6, and 0.51 (95% CI 0.36-0.72) for CCI > 6, respectively, all in relation to those with CCI 0-2. Additionally, increasing morbidity was associated with reduced odds of return of spontaneous circulation (ROSC) and ROSC at hospital admission.

CONCLUSION: This large national study showed that increasing comorbidity decreased the chance of survival to 30 days in OHCA. This association remained after covariate adjustment.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Hirlekar G, Jonsson M, Karlsson T, et al. Comorbidity and survival in out-of-hospital cardiac arrest. Resuscitation. 2018. PMID: 30315837. doi:10.1016/j.resuscitation.2018.10.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。